Impact of urate-lowering therapy on the course of chronic kidney disease in patients with asymptomatic hyperuricemia: a meta-analysis of randomized controlled trials

Abstract

The presented study has been carried out to identify the effect of urate-lowering therapy with xanthine oxidase inhibitors on glomerular filtration rate and serum uric acid in patients with asymptomatic hyperuricemia and chronic kidney disease. A systematic review of randomized controlled trials has been conducted; its results based on meta-analysis has been evaluated.

A systematic search and selection of publications in Embase, PubMed, Cochrane Library, and eLibrary databases has been performed. The studied drugs were xanthine oxidase inhibitors: allopurinol and febuxostat. The study considered the following parameters such as efficacy endpoints, namely, glomerular filtration rate and serum uric acid after 3–15 months of follow-up. Clinical and methodological heterogeneity of the included randomized controlled trials has been assessed as well as publication bias and risk of systematic error. Synthesis has been performed using bivariate meta-analysis assessing residual statistical heterogeneity.

7 selected randomized controlled trials (1203 patients) have been included in the meta-analysis. This analysis revealed that medication urate-lowering therapy (allopurinol or febuxostat) was associated with higher glomerular filtration rate (+3.0 ml/min/1.73 m2; 95% confidence interval +0.4 to +5.6; p = 0.022) compared with the controls (placebo/no urate-lowering therapy) at 3–15 months of follow-up. Along with this, medication urate-lowering therapy (allopurinol or febuxostat) has been found to result in lower serum uric acid (−3.3 mg/dl; 95% confidence interval −3.8 to −2.8; р < 0.001) compared to the controls (placebo / no urate-lowering therapy) at 3–15 months of follow-up.

The results of the meta-analysis have demonstrated a positive role of allopurinol and febuxostat in increasing glomerular filtration rate and decreasing serum uric acid in patients with chronic kidney disease and asymptomatic hyperuricemia. The presented data suggest that therapeutic measures aimed at the elimination of asymptomatic hyperuricemia, including the use of xanthine oxidase inhibitors, may be important in slowing the progression of chronic kidney failure and may be additional factors of nephroprotection.

Keywords

asymptomatic hyperuricemia / urate-lowering therapy / chronic kidney disease / nephroprotection / meta-analysis of randomized controlled trials

References

[1] Shalnova SA, Deev AD, Artamonova GV, et al. Hyperuricemia and its correlates in the Russian population (results of ESSE-RF epidemiological study). Rational Pharmacotherapy in Cardiology. 2014;10(2):153–159. (In Russ.) DOI: 10.20996/1819-6446-2014-10-2-153-159

[2] Шальнова С.А., Деев А.Д., Артамонова Г.В. и др. Гиперурикемия и ее корреляты в российской популяции (результаты эпидемиологического исследования ЭССЕ-РФ) // Рациональная фармакотерапия в кардиологии. 2014. Т. 10, № 2. С. 153–159. DOI: 10.20996/1819-6446-2014-10-2-153-159

[3] Chen-Xu M, Yokose C, Rai SK, et al. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: The National Health and Nutrition Examination Survey, 2007–2016. Arthritis Rheumatol. 2019;71(6):991–999. DOI: 10.1002/art.40807

[4] Chen-Xu M., Yokose C., Rai S.K. et al. Contemporary prevalence of gout and hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007–2016 // Arthritis Rheumatol. 2019. Vol. 71, No. 6. P. 991–999. DOI: 10.1002/art.40807

[5] Trifirò G, Morabito P, Cavagna L, et al. Epidemiology of gout and hyperuricaemia in Italy during the years 2005-2009: a nationwide population-based study. Ann Rheum Dis. 2013;72(5):694–700. DOI: 10.1136/annrheumdis-2011-201254

[6] Trifirò G., Morabito P., Cavagna L. et al. Epidemiology of gout and hyperuricaemia in Italy during the years 2005–2009: a nationwide population-based study // Ann. Rheum. Dis. 2013. Vol. 72, No. 5. P. 694–700. DOI: 10.1136/annrheumdis-2011-201254

[7] Mazurov VI, Bashkinov RA, Gaidukova IZ, Fonturenko AYu. The effect of asymptomatic hyperuricemia on comorbidities and the possibility of its correction. RMJ. 2021;7:24–30. (In Russ.)

[8] Мазуров В.И., Башкинов Р.А., Гайдукова И.З., Фонтуренко А.Ю. Влияние бессимптомной гиперурикемии на коморбидные заболевания и возможности ее коррекции // РМЖ. 2021. № 7. С. 24–30.

[9] Yip K, Cohen RE, Pillinger MH. Asymptomatic hyperuricemia: is it really asymptomatic? Curr Opin Rheumatol. 2020;32(1):71–79. DOI: 10.1097/BOR.0000000000000679

[10] Yip K., Cohen R.E., Pillinger M.H. Asymptomatic hyperuricemia: is it really asymptomatic? // Curr. Opin. Rheumatol. 2020. Vol. 32, No. 1. P. 71–79. DOI: 10.1097/BOR.0000000000000679

[11] Zhang S, Wang Y, Cheng J, et al. Hyperuricemia and cardiovascular disease. Curr Pharm Des. 2019;25(6):700–709. DOI: 10.2174/1381612825666190408122557

[12] Zhang S., Wang Y., Cheng J. et al. Hyperuricemia and cardiovascular disease // Curr. Pharm. Des. 2019. Vol. 25, No. 6. P. 700–709. DOI: 10.2174/1381612825666190408122557

[13] Borghi C, Agabiti-Rosei E, Johnson RJ, et al. Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. Eur J Intern Med. 2020;80:1–11. DOI: 10.1016/j.ejim.2020.07.006

[14] Borghi C., Agabiti-Rosei E., Johnson R.J. et al. Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease // Eur. J. Intern. Med. 2020. Vol. 80. P. 1–11. DOI: 10.1016/j.ejim.2020.07.006

[15] Wang H, Zhang H, Sun L, Guo W. Roles of hyperuricemia in metabolic syndrome and cardiac-kidney-vascular system diseases. Am J Transl Res. 2018;10(9):2749–2763.

[16] Wang H., Zhang H., Sun L., Guo W. Roles of hyperuricemia in metabolic syndrome and cardiac-kidney-vascular system diseases // Am. J. Transl. Res. 2018. Vol. 10, No. 9. P. 2749–2763.

[17] Borghi C, Tykarski A, Widecka K, et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk. Cardiol J. 2018;25(5):545–563. DOI: 10.5603/CJ.2018.0116

[18] Borghi C., Tykarski A., Widecka K. et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk // Cardiol. J. 2018. Vol. 25, No. 5. P. 545–563. DOI: 10.5603/CJ.2018.0116

[19] Borghi C, Domienik-Karłowicz J, Tykarski A, et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk: 2021 update. Cardiol J. 2021;28(1):1–14. DOI: 10.5603/CJ.a2021.0001

[20] Borghi C., Domienik-Karłowicz J., Tykarski A. et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk: 2021 update // Cardiol. J. 2021. Vol. 28, No. 1. P. 1–14. DOI: 10.5603/CJ.a2021.0001

[21] Chazova IE, Zhernakova YuV, Kislyak OA, et al. Consensus on patients with hyperuricemia and high cardiovascular risk treatment: 2022. Systemic Hypertension. 2022;19(1):5–22. (In Russ.) DOI: 10.38109/2075-082X-2022-1-5-22

[22] Чазова И.Е., Жернакова Ю.В., Кисляк О.А. и др. Консенсус по ведению пациентов с гиперурикемией и высоким сердечно-сосудистым риском: 2022 // Системные гипертензии. 2022. Т. 19, № 1. С. 5–22. DOI: 10.38109/2075-082X-2022-1-5-22

[23] Sánchez-Lozada LG. The Pathophysiology of Uric Acid on Renal Diseases. Contrib Nephrol. 2018;192:17–24. DOI: 10.1159/000484274

[24] Sánchez-Lozada L.G. The pathophysiology of uric acid on renal diseases // Contrib. Nephrol. 2018. Vol. 192. P. 17–24. DOI: 10.1159/000484274

[25] Kuwabara M, Niwa K, Hisatome I, et al. Asymptomatic hyperuricemia without comorbidities predicts cardiometabolic diseases: Five-Year Japanese Cohort Study. Hypertension. 2017;69(6):1036–1044. DOI: 10.1161/HYPERTENSIONAHA.116.08998

[26] Kuwabara M., Niwa K., Hisatome I. et al. Asymptomatic hyperuricemia without comorbidities predicts cardiometabolic diseases: Five-year Japanese cohort study // Hypertension. 2017. Vol. 69, No. 6. P. 1036–1044. DOI: 10.1161/HYPERTENSIONAHA.116.08998

[27] Koo BS, Jeong HJ, Son CN, et al. J-shaped relationship between chronic kidney disease and serum uric acid levels: a cross-sectional study on the Korean population. J Rheum Dis. 2021;28(4):225–233. DOI: 10.4078/jrd.2021.28.4.225

[28] Koo B.S., Jeong H.J., Son C.N. et al. J-shaped relationship between chronic kidney disease and serum uric acid levels: a cross-sectional Study on the Korean Population // J. Rheum. Dis. 2021. Vol. 28, No. 4. P. 225–233. DOI: 10.4078/jrd.2021.28.4.225

[29] Tsai CW, Lin SY, Kuo CC, Huang CC. Serum uric acid and progression of kidney disease: a longitudinal analysis and mini-review. PLoS One. 2017;12(1):e0170393. DOI: 10.1371/journal.pone.0170393

[30] Tsai C.W., Lin S.Y., Kuo C.C., Huang C.C. Serum uric acid and progression of kidney disease: a longitudinal analysis and mini-review // PLoS One. 2017. Vol. 12, No. 1. P. e0170393. DOI: 10.1371/journal.pone.0170393

[31] Li L, Yang C, Zhao Y, et al. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: A systematic review and meta-analysis based on observational cohort studies. BMC Nephrol. 2014;15:122. DOI: 10.1186/1471-2369-15-122

[32] Li L., Yang C., Zhao Y. et al. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: A systematic review and meta-analysis based on observational cohort studies // BMC Nephrol. 2014. Vol. 15. P. 122. DOI: 10.1186/1471-2369-15-122

[33] Zhu P, Liu Y, Han L, et al. Serum uric acid is associated with incident chronic kidney disease in middle-aged populations: a meta-analysis of 15 cohort studies. PLoS One. 2014;9(6):e100801. DOI: 10.1371/journal.pone.0100801

[34] Zhu P., Liu Y., Han L. et al. Serum uric acid is associated with incident chronic kidney disease in middle-aged populations: a meta-analysis of 15 cohort studies // PLoS One. 2014. Vol. 9, No. 6. P. e100801. DOI: 10.1371/journal.pone.0100801

[35] Li YL, Wang L, Li J, et al. The correlation between uric acid and the incidence and prognosis of kidney diseases: a systematic review and meta-analysis of cohort studies. Zhonghua Nei Ke Za Zhi. 2011;50(7):555–561. (In Chinese)

[36] Li Y.L., Wang L., Li J. et al. The correlation between uric acid and the incidence and prognosis of kidney diseases: a systematic review and meta-analysis of cohort studies // Zhonghua Nei Ke Za Zhi. 2011. Vol. 50, No. 7. P. 555–561. (In Chinese)

[37] Sharma G, Dubey A, Nolkha N, Singh JA. Hyperuricemia, urate-lowering therapy, and kidney outcomes: a systematic review and meta-analysis. Ther Adv Musculoskelet Dis. 2021;13:1759720X211016661. DOI: 10.1177/1759720X211016661

[38] Sharma G., Dubey A., Nolkha N., Singh J.A. Hyperuricemia, urate-lowering therapy, and kidney outcomes: a systematic review and meta-analysis // Ther. Adv. Musculoskelet. Dis. 2021. Vol. 13. P. 1759720X211016661. DOI: 10.1177/1759720X211016661

[39] Xia X, Luo Q, Li B, et al. Serum uric acid and mortality in chronic kidney disease: A systematic review and meta-analysis. Metabolism. 2016;65(9):1326–1341. DOI: 10.1016/j.metabol.2016.05.009

[40] Xia X., Luo Q., Li B. et al. Serum uric acid and mortality in chronic kidney disease: a systematic review and meta-analysis // Metabolism. 2016. Vol. 65, No. 9. P. 1326–1341. DOI: 10.1016/j.metabol.2016.05.009

[41] Luo Q, Xia X, Li B, et al. Serum uric acid and cardiovascular mortality in chronic kidney disease: a meta-analysis. BMC Nephrol. 2019;20(1):18. DOI: 10.1186/s12882-018-1143-7

[42] Luo Q., Xia X., Li B. et al. Serum uric acid and cardiovascular mortality in chronic kidney disease: a meta-analysis // BMC Nephrol. 2019. Vol. 20, No. 1. P. 18. DOI: 10.1186/s12882-018-1143-7

[43] GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709–733. DOI: 10.1016/S0140-6736(20)30045-3

[44] GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 // Lancet. 2020. Vol. 395, No. 10225. P. 709–733. DOI: 10.1016/S0140-6736(20)30045-3

[45] Levey AS, Atkins R, Coresh J, et al. Chronic kidney disease as a global public health problem: approaches and initiatives – a position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 2007;72(3):247–259. DOI: 10.1038/sj.ki.5002343

[46] Levey A.S., Atkins R., Coresh J. et al. Chronic kidney disease as a global public health problem: approaches and initiatives – a position statement from kidney disease improving global outcomes // Kidney Int. 2007. Vol. 72, No. 3. P. 247–259. DOI: 10.1038/sj.ki.5002343

[47] Clinical recommendations. Chronic kidney disease (CKD). Nephrology (Saint-Petersburg). 2021;25(5):10–82. (In Russ.)

[48] Клинические рекомендации. Хроническая болезнь почек (ХБП) // Нефрология. 2021. Т. 25, № 5. С. 10–82.

[49] Chewcharat A, Chen Y, Thongprayoon C, et al. Febuxostat as a renoprotective agent for treatment of hyperuricaemia: a meta-analysis of randomised controlled trials. Intern Med J. 2021;51(5):752–762. DOI: 10.1111/imj.14814

[50] Chewcharat A., Chen Y., Thongprayoon C. et al. Febuxostat as a renoprotective agent for treatment of hyperuricaemia: a meta-analysis of randomised controlled trials // Intern. Med. J. 2021. Vol. 51, No. 5. P. 752–762. DOI: 10.1111/imj.14814

[51] Sampson AL, Singer RF, Walters GD. Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease. Cochrane Database Syst Rev. 2017;10(10):CD009460. DOI: 10.1002/14651858.CD009460.pub2

[52] Sampson A.L., Singer R.F., Walters G.D. Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease // Cochrane Database Syst. Rev. 2017. Vol. 10, No. 10. P. CD009460. DOI: 10.1002/14651858.CD009460.pub2

[53] Liu X, Liu K, Sun Q, et al. Efficacy and safety of febuxostat for treating hyperuricemia in patients with chronic kidney disease and in renal transplant recipients: A systematic review and meta-analysis. Exp Ther Med. 2018;16(3):1859–1865. DOI: 10.3892/etm.2018.6367

[54] Liu X., Liu K., Sun Q. et al. Efficacy and safety of febuxostat for treating hyperuricemia in patients with chronic kidney disease and in renal transplant recipients: a systematic review and meta-analysis // Exp. Ther. Med. 2018. Vol. 16, No. 3. P. 1859–1865. DOI: 10.3892/etm.2018.6367

[55] Liu X, Zhai T, Ma R, et al. Effects of uric acid-lowering therapy on the progression of chronic kidney disease: a systematic review and meta-analysis. Ren Fail. 2018;40(1):289–297. DOI: 10.1080/0886022X.2018.1456463

[56] Liu X., Zhai T., Ma R. et al. Effects of uric acid-lowering therapy on the progression of chronic kidney disease: a systematic review and meta-analysis // Ren. Fail. 2018. Vol. 40, No. 1. P. 289–297. DOI: 10.1080/0886022X.2018.1456463

[57] Wang H, Wei Y, Kong X, Xu D. Effects of urate-lowering therapy in hyperuricemia on slowing the progression of renal function: a meta-analysis. J Ren Nutr. 2013;23(5):389–396. DOI: 10.1053/j.jrn.2012.08.005

[58] Wang H., Wei Y., Kong X., Xu D. Effects of urate-lowering therapy in hyperuricemia on slowing the progression of renal function: a meta-analysis // J. Ren. Nutr. 2013. Vol. 23, No. 5. P. 389–396. DOI: 10.1053/j.jrn.2012.08.005

[59] Zhang YF, He F, Ding HH, et al. Effect of uric-acid-lowering therapy on progression of chronic kidney disease: a meta-analysis. J Huazhong Univ Sci Technolog Med Sci. 2014;34(4):476–481. DOI: 10.1007/s11596-014-1302-4

[60] Zhang Y.F., He F., Ding H.H. et al. Effect of uric-acid-lowering therapy on progression of chronic kidney disease: a meta-analysis // J. Huazhong Univ. Sci. Technolog. Med. Sci. 2014. Vol. 34, No. 4. P. 476–481. DOI: 10.1007/s11596-014-1302-4

[61] Bayram D, Tuğrul Sezer M, İnal S, et al. The effects of allopurinol on metabolic acidosis and endothelial functions in chronic kidney disease patients. Clin Exp Nephrol. 2015;19(3):443–449. DOI: 10.1007/s10157-014-1012-z

[62] Bayram D., Tuğrul Sezer M., İnal S. et al. The effects of allopurinol on metabolic acidosis and endothelial functions in chronic kidney disease patients // Clin. Exp. Nephrol. 2015. Vol. 19, No. 3. P. 443–449. DOI: 10.1007/s10157-014-1012-z

[63] Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5(8):1388–1393. DOI: 10.2215/CJN.01580210

[64] Goicoechea M., de Vinuesa S.G., Verdalles U. et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk // Clin. J. Am. Soc. Nephrol. 2010. Vol. 5, No. 8. P. 1388–1393. DOI: 10.2215/CJN.01580210

[65] Mukri MNA, Kong WY, Mustafar R, et al. Role of febuxostat in retarding progression of diabetic kidney disease with asymptomatic hyperuricemia: A 6-months open-label, randomized controlled trial. EXCLI J. 2018;17:563–575. DOI: 10.17179/excli2018-1256

[66] Mukri M.N.A., Kong W.Y., Mustafar R. et al. Role of febuxostat in retarding progression of diabetic kidney disease with asymptomatic hyperuricemia: a 6-months open-label, randomized controlled trial // EXCLI J. 2018. Vol. 17. P. 563–575. DOI: 10.17179/excli2018-1256

[67] Sircar D, Chatterjee S, Waikhom R, et al. Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis. 2015;66(6):945–950. DOI: 10.1053/j.ajkd.2015.05.017

[68] Sircar D., Chatterjee S., Waikhom R. et al. Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, placebo-controlled trial // Am. J. Kidney Dis. 2015. Vol. 66, No. 6. P. 945–950. DOI: 10.1053/j.ajkd.2015.05.017

[69] Shi Y, Chen W, Jalal D, et al. Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial. Kidney Blood Press Res. 2012;35(3):153–160. DOI: 10.1159/000331453

[70] Shi Y., Chen W., Jalal D. et al. Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial // Kidney Blood Press Res. 2012. Vol. 35, No. 3. P. 153–160. DOI: 10.1159/000331453

[71] Badve SV, Pascoe EM, Tiku A, et al. Effects of allopurinol on the progression of chronic kidney disease. N Engl J Med. 2020;382(26):2504–2513. DOI: 10.1056/NEJMoa1915833

[72] Badve S.V., Pascoe E.M., Tiku A. et al. Effects of allopurinol on the progression of chronic kidney disease // N. Engl. J. Med. 2020. Vol. 382, No. 26. P. 2504–2513. DOI: 10.1056/NEJMoa1915833

[73] Kimura K, Hosoya T, Uchida S, et al. Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial. Am J Kidney Dis. 2018;72(6):798–810. DOI: 10.1053/j.ajkd.2018.06.028

[74] Kimura K., Hosoya T., Uchida S. et al. Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial // Am. J. Kidney Dis. 2018. Vol. 72, No. 6. P. 798–810. DOI: 10.1053/j.ajkd.2018.06.028

[75] Bose B, Badve SV, Hiremath SS, et al. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2014;29(2):406–413. DOI: 10.1093/ndt/gft378

[76] Bose B., Badve S.V., Hiremath S.S. et al. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis // Nephrol. Dial. Transplant. 2014. Vol. 29, No. 2. P. 406–413. DOI: 10.1093/ndt/gft378

[77] Zhang L, An K, Mou X, et al. Effect of urate-lowering therapy on the progression of kidney function in patients with asymptomatic hyperuricemia: a systematic review and meta-analysis. Front Pharmacol. 2022;12:795082. DOI: 10.3389/fphar.2021.795082

[78] Zhang L., An K., Mou X. et al. Effect of urate-lowering therapy on the progression of kidney function in patients with asymptomatic hyperuricemia: a systematic review and meta-analysis // Front. Pharmacol. 2022. Vol. 12. P. 795082. DOI: 10.3389/fphar.2021.795082

[79] Doria A, Galecki AT, Spino C, et al. Serum urate lowering with allopurinol and kidney function in type 1 diabetes. N Engl J Med. 2020;382(26):2493–2503. DOI: 10.1056/NEJMoa1916624

[80] Doria A., Galecki A.T., Spino C. et al. Serum urate lowering with allopurinol and kidney function in type 1 diabetes // N. Engl. J. Med. 2020. Vol. 382, No. 26. P. 2493–2503. DOI: 10.1056/NEJMoa1916624

[81] Higgins JPT, Thomas J, (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 [Internet]. Cochrane. 2022. Available from: https://training.cochrane.org/handbook/archive/v6.3. Accessed: 07.07.2023.

[82] Cochrane Handbook for Systematic Reviews of Interventions version 6.3. Ed. by J.P.T. Higgins, J. Thomas [Электронный ресурс] // Cochrane. 2022. Режим доступа: https://training.cochrane.org/handbook/archive/v6.3. Дата обращения: 07.07.2023.

[83] Nashar K, Fried LF. Hyperuricemia and the progression of chronic kidney disease: is uric acid a marker or an independent risk factor? Adv Chronic Kidney Dis. 2012;19(6):386–391. DOI: 10.1053/j.ackd.2012.05.004

[84] Nashar K., Fried L.F. Hyperuricemia and the progression of chronic kidney disease: is uric acid a marker or an independent risk factor? // Adv. Chronic Kidney Dis. 2012. Vol. 19, No. 6. P. 386–391. DOI: 10.1053/j.ackd.2012.05.004

[85] Piani F, Johnson RJ. Does gouty nephropathy exist, and is it more common than we think? Kidney Int. 2021;99(1):31–33. DOI: 10.1016/j.kint.2020.10.015

[86] Piani F., Johnson R.J. Does gouty nephropathy exist, and is it more common than we think? // Kidney Int. 2021. Vol. 99, No. 1. P. 31–33. DOI: 10.1016/j.kint.2020.10.015

[87] Bardin T, Nguyen QD, Tran KM, et al. A cross-sectional study of 502 patients found a diffuse hyperechoic kidney medulla pattern in patients with severe gout. Kidney Int. 2021;99(1):218–226. DOI: 10.1016/j.kint.2020.08.024

[88] Bardin T., Nguyen Q.D., Tran K.M. et al. A cross-sectional study of 502 patients found a diffuse hyperechoic kidney medulla pattern in patients with severe gout // Kidney Int. 2021. Vol. 99, No. 1. P. 218–226. DOI: 10.1016/j.kint.2020.08.024

[89] Kim YJ, Oh SH, Ahn JS, et al. The crucial role of xanthine oxidase in CKD progression associated with hypercholesterolemia. Int J Mol Sci. 2020;21(20):7444. DOI: 10.3390/ijms21207444

[90] Kim Y.J., Oh S.H., Ahn J.S. et al. The crucial role of xanthine oxidase in CKD progression associated with hypercholesterolemia // Int. J. Mol. Sci. 2020. Vol. 21, No. 20. P. 7444. DOI: 10.3390/ijms21207444

[91] Sato Y, Feig DI, Stack AG, et al. The case for uric acid-lowering treatment in patients with hyperuricaemia and CKD. Nat Rev Nephrol. 2019;15(12):767–775. DOI: 10.1038/s41581-019-0174-z

[92] Sato Y., Feig D.I., Stack A.G. et al. The case for uric acid-lowering treatment in patients with hyperuricaemia and CKD // Nat. Rev. Nephrol. 2019. Vol. 15, No. 12. P. 767–775. DOI: 10.1038/s41581-019-0174-z

[93] Zeng XX, Tang Y, Hu K, et al. Efficacy of febuxostat in hyperuricemic patients with mild-to-moderate chronic kidney disease: a meta-analysis of randomized clinical trials: A PRISMA-compliant article. Medicine (Baltimore). 2018;97(13):e0161. DOI: 10.1097/MD.0000000000010161

[94] Zeng X.X., Tang Y., Hu K. et al. Efficacy of febuxostat in hyperuricemic patients with mild-to-moderate chronic kidney disease: a meta-analysis of randomized clinical trials: A PRISMA-compliant article // Medicine (Baltimore). 2018. Vol. 97, No. 13. P. e0161. DOI: 10.1097/MD.0000000000010161

[95] Lin TC, Hung LY, Chen YC, et al. Effects of febuxostat on renal function in patients with chronic kidney disease: A systematic review and meta-analysis. Medicine (Baltimore). 2019;98(29):e16311. DOI: 10.1097/MD.0000000000016311

[96] Lin T.C., Hung L.Y., Chen Y.C. et al. Effects of febuxostat on renal function in patients with chronic kidney disease: A systematic review and meta-analysis // Medicine (Baltimore). 2019. Vol. 98, No. 29. P. e16311. DOI: 10.1097/MD.0000000000016311

[97] Zheng Y, Sun J. Febuxostat improves uric acid levels and renal function in patients with chronic kidney disease and hyperuricemia: a meta-analysis. Appl Bionics Biomech. 2022;2022:9704862. DOI: 10.1155/2022/9704862

[98] Zheng Y., Sun J. Febuxostat improves uric acid levels and renal function in patients with chronic kidney disease and hyperuricemia: a meta-analysis // Appl. Bionics Biomech. 2022. Vol. 2022. P. 9704862. DOI: 10.1155/2022/9704862

[99] Tien YY, Shih MC, Tien CP, et al. To treat or not to treat? Effect of urate-lowering therapy on renal function, blood pressure and safety in patients with asymptomatic hyperuricemia: a systematic review and network meta-analysis. J Am Board Fam Med. 2022;35(1):140–151. DOI: 10.3122/jabfm.2022.01.210273

[100] Tien Y.Y., Shih M.C., Tien C.P. et al. To treat or not to treat? Effect of urate-lowering therapy on renal function, blood pressure and safety in patients with asymptomatic hyperuricemia: a systematic review and network meta-analysis // J. Am. Board Fam. Med. 2022. Vol. 35, No. 1. P. 140–151. DOI: 10.3122/jabfm.2022.01.210273

[101] Sapankaew T, Thadanipon K, Ruenroengbun N, et al. Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials. BMC Nephrol. 2022;23(1):223. DOI: 10.1186/s12882-022-02850-3

[102] Sapankaew T., Thadanipon K., Ruenroengbun N. et al. Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials // BMC Nephrol. 2022. Vol. 23, No. 1. P. 223. DOI: 10.1186/s12882-022-02850-3

[103] Kanji T, Gandhi M, Clase CM, Yang R. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol. 2015;16:58. DOI: 10.1186/s12882-015-0047-z

[104] Kanji T., Gandhi M., Clase C.M., Yang R. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis // BMC Nephrol. 2015. Vol. 16. P. 58. DOI: 10.1186/s12882-015-0047-z

[105] Chazova IE, Zhernakova JuV, Kisliak OA, et al. Consensus on patients with hyperuricemia and high cardiovascular risk treatment. Systemic Hypertension. 2019;16(4):8–21. (In Russ). DOI: 10.26442/2075082X.2019.4.190686

[106] Чазова И.Е., Жернакова Ю.В., Кисляк О.А. и др. Консенсус по ведению пациентов с гиперурикемией и высоким сердечно-сосудистым риском // Системные гипертензии. 2019. Т. 16, № 4. С. 8–21. DOI: 10.26442/2075082X.2019.4.190686

[107] Drapkina OM, Mazurov VI, Martynov AI, et al. “Focus on hyperuricemia”. The resolution of the Expert Council. Cardiovascular Therapy and Prevention. 2023;22(4):3564. (In Russ.) DOI: 10.15829/1728-8800-2023-3564

[108] Драпкина О.М., Мазуров В.И., Мартынов А.И. и др. «В фокусе гиперурикемия». Резолюция Cовета экспертов // Кардиоваскулярная терапия и профилактика. 2023. Т. 22, № 4. С. 3564. DOI: 10.15829/1728-8800-2023-3564

RIGHTS & PERMISSIONS

Eco-Vector